Our antibody-dependent cell-mediated cytotoxicity (ADCC) assays can help you understand if your biologic engages target antigen, activating immune cells through their Fc receptors initiating cell death or alternatively determine if Fc-silencing approaches are effective.
We can optimize specific targets using non-radioactive labeling techniques, and the assay can be adapted to a variety of immune cells, from mixed cell populations (PBMCs) to isolated cells (e.g. NK cells).
As antibody-dependent cell-mediated phagocytosis (ADCP) is an important MOA for many monoclonal antibody therapeutics. Our ADCP assays use monocytes or macrophages as effector cells for phagocytosis of target cells, to understand the effectiveness of antibody engagement with specific antigens through their Fc receptors.
Our strong expertise in macrophage differentiation in vitro, combined with our bespoke approach and readout options, ensures a phagocytosis assay design tailored to you.
Complement-dependent cytotoxicity (CDC) assays allow evaluation of antibody-based therapeutics to activate the complement immune system, an innate response that also results in target cell death.
Cancer cells typically express high levels of complement inhibitor molecules, protecting them from this innate immune mechanism. We can support your understanding of the interaction between your biologic and the immune system, taking you to the clinic faster.
Please get in touch to learn more about our Killing Assays.